Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CATALENT, INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 45.63 USD | -0.35% | -3.98% | +1.38% | |
Financials (USD)
| Sales 2023 | 4,276 M | Sales 2024 * | 4,361 M | Capitalization | 8 226 M |
|---|---|---|---|---|---|
| Net income 2023 | -232 M | Net income 2024 * | 9 M | EV / Sales 2023 | 2,90x |
| Net Debt 2023 | 4,569 M | Net Debt 2024 * | 4,207 M | EV / Sales 2024 * | 2,85x |
| P/E ratio 2023 | -33,6x | P/E ratio 2024 * | 857x | Employees | - |
| Yield 2023 | - | Yield 2024 * | - | Free-Float | 97.15% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.35% | ||
| 1 week | -3.98% | ||
| Current month | -8.69% | ||
| 1 month | +1.65% | ||
| 3 months | +4.13% | ||
| 6 months | -29.00% | ||
| Current year | +1.38% |
1 week
44.65
47.87
1 month
44.6551.79
Current year
31.4574.49
1 year
31.4581.72
3 years
31.45142.64
5 years
29.23142.64
10 years
18.92142.64
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 2022 | |
Ricky Hopson
PRN | Corporate Officer/Principal | 47 | 2022 |
Steven Fasman
ADM | Chief Administrative Officer | 61 | 2022 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 2015 | |
Jack Stahl
BRD | Director/Board Member | 70 | 2014 |
Gregory Lucier
BRD | Director/Board Member | 59 | 2015 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.21% | 8 M$ | -10.01% | ||
| 0.83% | 2 M$ | -7.95% | ||
| 0.60% | 30 M$ | +4.88% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-26 | 45.63 | -0.35% | 902,296 |
| 23-09-25 | 45.79 | +0.99% | 1,962,607 |
| 23-09-22 | 45.34 | -2.60% | 1,642,151 |
| 23-09-21 | 46.55 | -3.52% | 1,628,993 |
| 23-09-20 | 48.25 | +1.54% | 1,242,778 |
Delayed Quote Nyse, September 26, 2023 at 04:03 pm EDT
More quotes
Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows:
- subcontracted manufacturing services (48.5%)
- provision of development services (43.2%);
- clinical supply services (8.3%).
Net sales are distributed geographically as follows: the United States (62.9%), Europe (30.5%) and other (6.6%).
Sector
Pharmaceuticals
Calendar
2023-11-06
- Q1 2024 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
45.63USD
Average target price
52.00USD
Spread / Average Target
+13.96%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +1.38% | 8 226 M $ | |
| -16.47% | 8 401 M $ | |
| 0.00% | 8 423 M $ | |
| -30.00% | 8 467 M $ | |
| -27.49% | 7 835 M $ | |
| -17.88% | 7 520 M $ | |
| +17.83% | 7 432 M $ | |
| -0.23% | 7 192 M $ | |
| -19.78% | 9 469 M $ | |
| +55.32% | 9 671 M $ |
